Comparison of different starting gonadotropin doses (50, 75 and 100 IU daily) for ovulation induction combined with intrauterine insemination
- PMID: 22736041
- PMCID: PMC3439605
- DOI: 10.1007/s00404-012-2414-3
Comparison of different starting gonadotropin doses (50, 75 and 100 IU daily) for ovulation induction combined with intrauterine insemination
Abstract
Purpose: To prevent multiple pregnancies the goal of ovulation induction by gonadotropins is to achieve only mono-follicular development. The most important issue is therefore to determine the starting dose. The aim of this study is to compare three different starting doses of follitropin beta to assess the lowest effective dose.
Methods: We evaluated 92 cycles with ovarian stimulation for patients with unexplained infertility, anovulatory disorder or mild male factor. We prospectively divided patients into 50, 75 and 100 IU groups based on patients' response to clomiphene citrate treatment.
Results: We performed 87 intrauterine inseminations (95 % of cycles with ovulation induction). Five cycles were cancelled. We achieved 15 pregnancies; total pregnancy rate was 18 %. Pregnancy rate was 22, 10 and 28 % in 50, 75 and 100 IU follitropin beta groups. The average number of follicles was 2.0 ± 0.8, 2.2 ± 1.1 and 2.5 ± 1.8 (ns), total dose of gonadotropins (IU) 483 ± 192, 600 ± 151 and 830 ± 268 (p < 0.001), respectively. We observed one case of twins in 75 and 100 IU treatment group, as well (25 % risk).
Conclusions: This study suggests that based on the dose which was chosen according to clomiphene citrate response, all treatment regimes were effective for ovulation induction. 50 IU of follitropin beta daily is the appropriate starting dose to support ovulation for clomiphene citrate-sensitive women. The disadvantage may be an increased risk of cycle cancellation due to low ovarian response. Daily doses 75 or 100 IU of rFSH increase total consumption of gonadotropins.
Similar articles
-
Ovulation induction with minimal dose of follitropin alfa: a case series study.Reprod Biol Endocrinol. 2011 Oct 24;9:142. doi: 10.1186/1477-7827-9-142. Reprod Biol Endocrinol. 2011. PMID: 22024419 Free PMC article.
-
[Mono-follicular development--the objective of ovulation induction with follitropin beta combined with intrauterine insemination].Ceska Gynekol. 2008 Apr;73(2):93-7. Ceska Gynekol. 2008. PMID: 18567427 Czech.
-
Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.BJOG. 2003 Dec;110(12):1072-7. BJOG. 2003. PMID: 14664878 Clinical Trial.
-
Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.Reprod Biol Endocrinol. 2014 Jun 18;12:52. doi: 10.1186/1477-7827-12-52. Reprod Biol Endocrinol. 2014. PMID: 24942155 Free PMC article. Clinical Trial.
-
Prevention of multiple pregnancies in gonadotropin-insemination cycles.Curr Opin Obstet Gynecol. 2022 Jun 1;34(3):101-106. doi: 10.1097/GCO.0000000000000777. Epub 2022 Feb 25. Curr Opin Obstet Gynecol. 2022. PMID: 35645007 Review.
Cited by
-
Effects of donor sperm on perinatal and neonatal outcomes resulting from in vitro fertilization-intracytoplasmic sperm injection and embryo transfer cycles: a retrospective cohort study.Ann Transl Med. 2022 Aug;10(15):819. doi: 10.21037/atm-21-5492. Ann Transl Med. 2022. PMID: 36034991 Free PMC article.
-
Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD005356. doi: 10.1002/14651858.CD005356.pub3. Cochrane Database Syst Rev. 2021. PMID: 34739136 Free PMC article.
References
-
- Arici A, Byrd W, Bradshaw K, Kutteh WH, Marshburn P, Carr BR. Evaluation of clomiphene citrate and human chorionic gonadotropin treatment: a prospective, randomized, crossover study during intrauterine insemination cycles. Fertil Steril. 1994;61:314–318. - PubMed
-
- Balasch J, Ballesca JL, Pimentel C, Creus M, Fabregues F, Vanrell JA. Late low-dose pure follicle stimulating hormone for ovarian stimulation in intra-uterine insemination cycles. Hum Reprod. 1994;9:1863–1866. - PubMed
-
- Balen A, Platteau P, Andersen AN, Devroey P, Helmgaard L, Arce JC. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod. 2007;22:1816–1823. doi: 10.1093/humrep/dem075. - DOI - PubMed
-
- Calaf AJ, Ruiz Balda JA, Romeu SA, et al. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG. 2003;110:1072–1077. - PubMed
-
- Coelingh Bennink HJ, Fauser BC, Out HJ. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertil Steril. 1998;69:19–25. doi: 10.1016/S0015-0282(97)00423-8. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous